

1 **Supplementary Information**

2 **Challenges and advances for huntingtin detection in cerebrospinal fluid: in support of**
3 **relative quantification**

4 Rachel J. Harding^{1,2,3}, Yuanyun Xie⁴, Nicholas S. Caron⁵, Hailey Findlay-Black⁵, Caroline Lyu², Nalini
5 Potluri⁴, Renu Chandrasekaran¹, Michael R. Hayden⁵, Blair R. Leavitt⁵, Douglas R. Langbehn⁶, Amber
6 L. Southwell⁴

7 ¹ *Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON M5S 3M2, Canada*

8 ² *Structural Genomics Consortium, University of Toronto, Toronto, ON M5G 1L7, Canada*

9 ³ *Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON M5S 1A8, Canada*

10 ⁴ *Burnett School of Biomedical Sciences, University of Central Florida, Orlando, FL, 32827, USA*

11 ⁵ *Centre for Molecular Medicine and Therapeutics, The University of British Columbia, Vancouver, BC*
12 *V5Z 4H4 Canada*

13 ⁶ *Department of Psychiatry, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA*


14 **Corresponding Author:** Amber L. Southwell; amber.southwell@ucf.edu

15

16 **Supplementary Table 1. Primer sequences used in this study.**


Primer	Sequence
Forward - HTT aa. 1 BamHI	GATCGGATCCATGGCGACCCTGGAAAAGCTG
Reverse - HTT aa. 586 NotI	GATCGCGGCCGCGTCTAACACAATTTCAGAACTGTC
Forward - pCI Neo CMV	GCTCACATGGCTCGACAGATCTTCA
Reverse - pCI Neo CMV	CTAGTTGTGGTTTGTCCAAACTCATC
Forward - HTT aa. 1744 EcoRI	GATCGAATTCAGGTTTCTATTACAACCTGGTTG
Forward - HTT aa. 1744 EcoRI + ATG	GATCGAATTCATGAGGTTTCTATTACAACCTGGTTG
Reverse - HTT aa. 2234 NotI	GATCGCGGCCGCGACCACCACCAGGTACTGTGC
Forward - HTT aa. 1 EcoRI	GATCGAATTCATGGCGACCCTGGAAAAGCTG
Reverse - HTT aa. 90 NotI	GATCGCGGCCGCGTCCGGTGCAGCGGCTCCTC
Reverse - HTT aa. 171 NotI	GATCGCGGCCGCTCGAGCTGTAACCTTGAAG

17



18


19 **Supplementary Figure 1. SDS-PAGE analysis of purified HTT allelic series.** ~2-5 μ g of each HTT
 20 protein assessed by 4-20% Tris-Glycine SDS-PAGE showing >85% purity of all samples as
 21 determined by densitometry analysis.



22

23 **Supplementary Figure 2. Mapping HDB4 epitopes with recombinant HTT proteins.** A.
 24 Recombinant HTT fragments, including a C-terminal fragment (aa. 1744-2234) that includes the
 25 immunogen used to raise HDB4 (aa. 1844-2131), N410, N489, and N589 as well as full-length HTT were
 26 used to investigate the specificity of HDB4 in denatured conditions. HDB4 recognizes full-length HTT and
 27 the C-terminal fragment as expected, but also the N-terminal fragments. B. Exon 1, N171, and N586 HTT
 28 constructs as well as a GFP construct were transfected into HEK293 cells. Cell lysates were separated by
 29 PAGE, transferred to nitrocellulose, and blotted with either BKP1 (left), which recognizes the first 17 N-
 30 terminal amino acids of HTT or HDB4 (right). We found that both antibodies recognized all three HTT
 31 fragments, but not GFP. Faint bands above the 250 kDa marker, likely the FL endogenous cellular HTT
 32 protein, were also seen in all lanes of both blots, including the not transfected cell lysate.


33



34

35 **Supplementary Figure 3. ELISA analysis of MW1-ataxin-3 interaction with different polyQ tract**
36 **lengths.** Representative ELISA showing binding profile of MW1 to full-length Ataxin-3 with Q10 or
37 Q80. Error bars are S.D. of three intra-assay replicates. Data fitted in GraphPad Prism with specific
38 binding with hill slope model.

39



40

41 **Supplementary Figure 4. Complete western blot analysis of full-length HTT allelic series**
42 **proteins with MW1 and EPR5526 antibodies.** Two replicates in addition to data shown in **Figure 2C**
43 of western blot analysis of full-length HTT allelic series spanning Q23 to Q66 with ~5 ng loaded per
44 lane. Blots probed with both α -HTT EPR5526 and α -polyQ MW1 shown separately and merged.